JP2018502572A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502572A5 JP2018502572A5 JP2017534345A JP2017534345A JP2018502572A5 JP 2018502572 A5 JP2018502572 A5 JP 2018502572A5 JP 2017534345 A JP2017534345 A JP 2017534345A JP 2017534345 A JP2017534345 A JP 2017534345A JP 2018502572 A5 JP2018502572 A5 JP 2018502572A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- bispecific antibody
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562099236P | 2015-01-02 | 2015-01-02 | |
| US62/099,236 | 2015-01-02 | ||
| US201562200363P | 2015-08-03 | 2015-08-03 | |
| US62/200,363 | 2015-08-03 | ||
| US201562261609P | 2015-12-01 | 2015-12-01 | |
| US62/261,609 | 2015-12-01 | ||
| PCT/US2015/068238 WO2016109774A1 (en) | 2015-01-02 | 2015-12-31 | Bispecific antibodies against plasma kallikrein and factor xii |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020128994A Division JP7003347B2 (ja) | 2015-01-02 | 2020-07-30 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502572A JP2018502572A (ja) | 2018-02-01 |
| JP2018502572A5 true JP2018502572A5 (enExample) | 2019-02-14 |
| JP6744313B2 JP6744313B2 (ja) | 2020-08-26 |
Family
ID=56285069
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534345A Active JP6744313B2 (ja) | 2015-01-02 | 2015-12-31 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2020128994A Active JP7003347B2 (ja) | 2015-01-02 | 2020-07-30 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2021150755A Active JP7241827B2 (ja) | 2015-01-02 | 2021-09-16 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2023035060A Active JP7635285B2 (ja) | 2015-01-02 | 2023-03-07 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020128994A Active JP7003347B2 (ja) | 2015-01-02 | 2020-07-30 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2021150755A Active JP7241827B2 (ja) | 2015-01-02 | 2021-09-16 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2023035060A Active JP7635285B2 (ja) | 2015-01-02 | 2023-03-07 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11390687B2 (enExample) |
| EP (2) | EP3240570B1 (enExample) |
| JP (4) | JP6744313B2 (enExample) |
| KR (2) | KR102959547B1 (enExample) |
| CN (2) | CN114316061B (enExample) |
| AU (2) | AU2015373910B2 (enExample) |
| CA (1) | CA2972800A1 (enExample) |
| CO (1) | CO2017007123A2 (enExample) |
| EA (1) | EA201791527A1 (enExample) |
| IL (2) | IL253180B2 (enExample) |
| MX (2) | MX2017008541A (enExample) |
| NZ (1) | NZ771568A (enExample) |
| WO (1) | WO2016109774A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2972800A1 (en) | 2015-01-02 | 2016-07-07 | Dyax Corp. | Bispecific antibodies against plasma kallikrein and factor xii |
| EP3325516B1 (en) * | 2015-07-21 | 2021-12-15 | Takeda Pharmaceutical Company Limited | A monoclonal antibody inhibitor of factor xiia |
| KR102569559B1 (ko) * | 2016-09-16 | 2023-08-23 | 다케다 파머수티컬 컴패니 리미티드 | 유전성 혈관부종에 대한 rna 바이오마커 |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| KR20210029298A (ko) * | 2017-08-16 | 2021-03-15 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16, 및 egfr, ccr4 또는 pd-l1에 결합하는 단백질 |
| KR20200067195A (ko) * | 2017-10-18 | 2020-06-11 | 리젠엑스바이오 인크. | 완전-인간 번역후 변형된 항체 치료제 |
| IL275536B2 (en) * | 2018-01-12 | 2025-06-01 | Genzyme Corp | Methods for quantification of polypeptides |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| JP7412001B2 (ja) * | 2018-06-08 | 2024-01-12 | 株式会社モダリス | 改変されたＣａｓ９タンパク質及びその用途 |
| WO2020014419A2 (en) * | 2018-07-11 | 2020-01-16 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1 |
| CN113164570B (zh) * | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| WO2020033702A1 (en) * | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| CA3108427A1 (en) * | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| WO2020086741A1 (en) * | 2018-10-24 | 2020-04-30 | Shire-Nps Pharmaceuticals, Inc. | Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions |
| CR20220025A (es) | 2019-07-26 | 2022-05-04 | Janssen Biotech Inc | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos |
| AU2020392243A1 (en) | 2019-11-28 | 2022-06-16 | Regenxbio Inc. | Microdystrophin gene therapy constructs and uses thereof |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| US20230390418A1 (en) * | 2020-10-29 | 2023-12-07 | Regenxbio Inc. | Vectorized factor xii antibodies and administration thereof |
| WO2022156799A1 (zh) * | 2021-01-25 | 2022-07-28 | 成都康弘生物科技有限公司 | 一种抗体及其用途 |
| CN114790245B (zh) * | 2021-01-25 | 2026-08-11 | 成都康弘生物科技有限公司 | 一种抗体及其用途 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| AU2022261268A1 (en) * | 2021-04-22 | 2023-11-16 | Guangdong Fapon Biopharma Inc. | Bispecific multifunctional fusion polypeptide |
| WO2024238407A2 (en) * | 2023-05-12 | 2024-11-21 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of treating dilated cardiomyopathy and heart failure |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| EP0832980B1 (en) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| GB8901859D0 (en) | 1989-01-27 | 1989-03-15 | Shield Diagnostics Limited | Diagnostic test |
| US5500349A (en) | 1989-01-27 | 1996-03-19 | Coagen Limited | Blood-coagulation factor XIIA β monoclonal antibody and immunoassay |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DK0737750T3 (da) | 1989-03-21 | 2003-09-01 | Vical Inc | Ekspression af exogene polynucleotidsekvenser i vertebrater |
| EP1001032A3 (en) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ZA911974B (en) | 1990-03-21 | 1994-08-22 | Res Dev Foundation | Heterovesicular liposomes |
| AU7793291A (en) | 1990-05-10 | 1991-11-27 | Cetus Corporation | Inhibitors of factor xii activation and applications thereof |
| ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| US6093399A (en) * | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | VECTOR PARTICLES RESISTANT TO INACTIVATION BY HUMAN SERUM. |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| AU6818094A (en) | 1993-04-22 | 1994-11-08 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| WO1995007994A2 (en) | 1993-09-15 | 1995-03-23 | Viagene, Inc. | Recombinant alphavirus vectors |
| DE69435223D1 (de) | 1993-10-25 | 2009-09-03 | Canji Inc | Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung |
| HUT75162A (en) | 1993-11-16 | 1997-04-28 | Depotech Corp | Vesicles with controlled release of actives |
| DE69535669T2 (de) | 1994-05-09 | 2008-12-04 | Oxford Biomedica (Uk) Ltd. | Retrovirale vektoren mit verminderter rekombinationsrate |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| GB9609262D0 (en) | 1996-05-02 | 1996-07-03 | Isis Innovation | Peptide library and method |
| DE69739286D1 (de) | 1996-05-06 | 2009-04-16 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
| WO2000053211A2 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| CN101260156A (zh) * | 2002-06-28 | 2008-09-10 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| CN101102819A (zh) | 2004-12-23 | 2008-01-09 | Csl百灵有限公司 | 血栓的形成和/或稳定化的预防 |
| GB0500487D0 (en) | 2005-01-11 | 2005-02-16 | Axis Shield Diagnostics Ltd | Forms of factor XIIa |
| US7932021B2 (en) | 2005-07-28 | 2011-04-26 | American Diagnostica, Inc. | Lupus anticoagulant testing |
| GB0607515D0 (en) | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| TWI496582B (zh) * | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| AU2009335643B2 (en) | 2008-12-18 | 2014-05-29 | Oregon Health & Science University | Anti-fXI antibodies and methods of use |
| ES2905545T3 (es) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| CN105859889B (zh) | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| KR102011156B1 (ko) | 2011-01-06 | 2019-08-16 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
| HRP20250164T1 (hr) | 2011-07-22 | 2025-04-11 | Csl Behring Gmbh | Inhibitorna monoklonska antitijela protiv faktora xii/xiia i njihove uporabe |
| EP2548892A1 (en) * | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
| JP5653860B2 (ja) | 2011-07-28 | 2015-01-14 | 富士フイルム株式会社 | 管壁の硬度測定方法および装置 |
| EP2765192A4 (en) | 2011-10-05 | 2015-04-15 | Chugai Pharmaceutical Co Ltd | ANTIGENBINDING MOLECULE FOR PREPARING A SPACE BETWEEN A PLASMA AND AN ANTIGEN WITH A SACCHARIDE CHAIN RECEPTOR BINDING DOMAIN |
| US9527927B2 (en) * | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| EP2623110A1 (en) * | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| US9783614B2 (en) | 2012-05-10 | 2017-10-10 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof |
| WO2014019644A1 (en) | 2012-07-31 | 2014-02-06 | Baxter International Inc. | Selective measurement of active human protease coagulation factors |
| WO2014089493A1 (en) | 2012-12-07 | 2014-06-12 | Vanderbilt University | Antibodies against factor xii and uses thereof |
| DK2946206T3 (en) * | 2013-01-20 | 2019-04-15 | Dyax Corp | EVALUATION, ANALYSIS AND TREATMENT OF PKAL-MEDIATED DISORDERS |
| JP2016513682A (ja) | 2013-03-15 | 2016-05-16 | ダイアックス コーポレーション | 抗血漿カリクレイン抗体 |
| CA2916399C (en) * | 2013-06-28 | 2022-08-02 | Marc Nolte | Combination therapy using a factor xii inhibitor and a c1-inhibitor |
| JP6693872B2 (ja) | 2013-07-25 | 2020-05-13 | シトムクス セラピューティクス，インコーポレイティド | 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法 |
| CA2972800A1 (en) | 2015-01-02 | 2016-07-07 | Dyax Corp. | Bispecific antibodies against plasma kallikrein and factor xii |
| EP3325516B1 (en) * | 2015-07-21 | 2021-12-15 | Takeda Pharmaceutical Company Limited | A monoclonal antibody inhibitor of factor xiia |
| EP3263803B1 (en) | 2016-06-30 | 2019-08-14 | ABB Schweiz AG | Substation |
-
2015
- 2015-12-31 CA CA2972800A patent/CA2972800A1/en active Pending
- 2015-12-31 IL IL253180A patent/IL253180B2/en unknown
- 2015-12-31 EP EP15876336.7A patent/EP3240570B1/en active Active
- 2015-12-31 US US15/541,066 patent/US11390687B2/en active Active
- 2015-12-31 KR KR1020247017566A patent/KR102959547B1/ko active Active
- 2015-12-31 IL IL298086A patent/IL298086B2/en unknown
- 2015-12-31 MX MX2017008541A patent/MX2017008541A/es unknown
- 2015-12-31 NZ NZ771568A patent/NZ771568A/en unknown
- 2015-12-31 EA EA201791527A patent/EA201791527A1/ru unknown
- 2015-12-31 CN CN202210054884.3A patent/CN114316061B/zh active Active
- 2015-12-31 CN CN201580075633.1A patent/CN107405399B/zh active Active
- 2015-12-31 EP EP25204079.5A patent/EP4670785A3/en active Pending
- 2015-12-31 WO PCT/US2015/068238 patent/WO2016109774A1/en not_active Ceased
- 2015-12-31 KR KR1020177021610A patent/KR102670705B1/ko active Active
- 2015-12-31 JP JP2017534345A patent/JP6744313B2/ja active Active
- 2015-12-31 AU AU2015373910A patent/AU2015373910B2/en active Active
-
2017
- 2017-06-26 MX MX2024000317A patent/MX2024000317A/es unknown
- 2017-07-17 CO CONC2017/0007123A patent/CO2017007123A2/es unknown
-
2020
- 2020-07-30 JP JP2020128994A patent/JP7003347B2/ja active Active
-
2021
- 2021-09-16 JP JP2021150755A patent/JP7241827B2/ja active Active
-
2022
- 2022-02-17 AU AU2022201076A patent/AU2022201076B2/en active Active
- 2022-06-13 US US17/838,769 patent/US12240918B2/en active Active
-
2023
- 2023-03-07 JP JP2023035060A patent/JP7635285B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020186248A5 (enExample) | ||
| CN106459220B (zh) | 适用于高通量筛选的新的双特异性形式 | |
| US11286312B2 (en) | Multispecific antibodies | |
| JP2016533174A5 (enExample) | ||
| KR102282691B1 (ko) | 개변된 헬퍼 파지를 사용하여 항원 결합 분자를 제작하는 방법 | |
| JP7203800B2 (ja) | ヌクレオチド・ライブラリー | |
| JP7549961B2 (ja) | 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット | |
| JP7209464B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 | |
| JP2017512063A5 (enExample) | ||
| JP2017529067A5 (enExample) | ||
| JP2017509335A5 (enExample) | ||
| JP2020500510A5 (enExample) | ||
| JP2014518883A5 (enExample) | ||
| JP2018512124A5 (enExample) | ||
| KR20190111946A (ko) | 1가 항-프로페르딘 항체 및 항체 단편 | |
| JP2019506839A5 (enExample) | ||
| RU2017134043A (ru) | Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью | |
| CN111526887A (zh) | 用于使血清中的蛋白质半衰期增加的组合物和方法 | |
| CN104955846B (zh) | 人源化抗hmgb1抗体或其抗原结合性片段 | |
| Henry et al. | A disulfide-stabilized human VL single-domain antibody library is a source of soluble and highly thermostable binders | |
| Aoki et al. | Engineering a low-immunogenic mirror-image VHH against vascular endothelial growth factor | |
| CA3218571A1 (en) | Methods of screening and expression of disulfide-bonded binding polypeptides | |
| JPWO2020071554A5 (enExample) | ||
| CN108699551B (zh) | 多肽文库 | |
| CN116063519B (zh) | 新型癌症免疫治疗抗体组合物 |